» Articles » PMID: 28561276

Intestinal Microbiota in Patients with Chronic Hepatitis C with and Without Cirrhosis Compared with Healthy Controls

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2017 Jun 1
PMID 28561276
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: The importance of the intestinal microbiota for the onset and clinical course of many diseases, including liver diseases like non-alcoholic steatohepatitis and cirrhosis, is increasingly recognized. However, the role of intestinal microbiota in chronic hepatitis C virus (HCV) infection remains unclear.

Methods: In a cross-sectional approach, the intestinal microbiota of 95 patients chronically infected with HCV (n=57 without cirrhosis [NO-CIR]; n=38 with cirrhosis [CIR]) and 50 healthy controls (HC) without documented liver diseases was analysed.

Results: Alpha diversity, measured by number of phylotypes (S) and Shannon diversity index (H'), decreased significantly from HC to NO-CIR to CIR. S and H' correlated negatively with liver elastography. Analysis of similarities revealed highly statistically significant differences in the microbial communities between HC, NO-CIR and CIR (R=.090; P<1.0×10 ). Stratifying for HCV genotypes even increased the differences. In addition, we observed distinct patterns in the relative abundance of genera being either positive or negative correlated with diseases status.

Conclusions: This study shows that not only the stage of liver disease but also HCV infection is associated with a reduced alpha diversity and different microbial community patterns. These differences might be caused by direct interactions between HCV and the microbiota or indirect interactions facilitated by the immune system.

Citing Articles

Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity.

Hupa-Breier K, Schenk H, Campos-Murguia A, Wellhoner F, Heidrich B, Dywicki J Mol Metab. 2025; 93:102104.

PMID: 39855563 PMC: 11815970. DOI: 10.1016/j.molmet.2025.102104.


Associations between changes in the gut microbiota and liver cirrhosis: a systematic review and meta-analysis.

Liu Y, Chen Z, Li C, Sun T, Luo X, Jiang B BMC Gastroenterol. 2025; 25(1):16.

PMID: 39806278 PMC: 11727502. DOI: 10.1186/s12876-025-03589-5.


Isolation of mucosa-associated microbiota dysbiosis in the ascending colon in hepatitis C virus post-sustained virologic response cirrhotic patients.

Midori Y, Nosaka T, Hiramatsu K, Akazawa Y, Tanaka T, Takahashi K Front Cell Infect Microbiol. 2024; 14:1371429.

PMID: 38650735 PMC: 11033736. DOI: 10.3389/fcimb.2024.1371429.


Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions.

Shah Y, Ali H, Tiwari A, Guevara-Lazo D, Nombera-Aznaran N, Pinnam B World J Hepatol. 2024; 16(1):17-32.

PMID: 38313244 PMC: 10835490. DOI: 10.4254/wjh.v16.i1.17.


Liver cirrhosis and complications from the perspective of dysbiosis.

Nie G, Zhang H, Xie D, Yan J, Li X Front Med (Lausanne). 2024; 10:1320015.

PMID: 38293307 PMC: 10824916. DOI: 10.3389/fmed.2023.1320015.